Form 4: Nuvation Bio Inc. Director Stock Option Grant

Nuvation Bio Inc. reports a stock option grant to Director Kim D. Blickenstaff for 123,397 shares at an exercise price of $4.79, with vesting tied to service anniversaries or annual meetings.

Summary

• Kim D. Blickenstaff, a Director at Nuvation Bio Inc., was granted stock options on May 21, 2026.
• The options are for 123,397 shares of Class A Common Stock.
• The exercise price for these options is $4.79 per share.
• Vesting of 100% of the shares is scheduled for the earlier of the one-year anniversary of the grant date (May 21, 2026) or the next shareholder annual meeting, contingent on continuous service.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard compensation mechanism for a director, aligning incentives without immediate financial impact.

Positives

• Director Kim D. Blickenstaff has been granted a significant stock option award, aligning their interests with the company's performance.
• The option grant provides a clear path to potential equity ownership for a key executive.

Risks

• The value of the stock options is subject to the future performance of Nuvation Bio Inc.'s stock price.
• Vesting is contingent on continuous service, meaning the options could be forfeited if service is terminated before vesting dates.

Future Outlook

The vesting schedule indicates a forward-looking incentive tied to continued employment and company performance over the next year and beyond.

Management Comments

• "100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 21, 2026); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date."

Industry Context

StockSavvy.ai notes that stock option grants to directors are a common practice in the biotechnology and pharmaceutical sectors to incentivize leadership and align executive interests with long-term shareholder value creation, especially for companies in development stages.

Stakeholder Impact

• Shareholders: The option grant aligns director incentives with shareholder interests, potentially leading to decisions that enhance long-term stock value.
• Employees: Standard compensation practice, reinforcing the company's approach to executive incentives.
• Management: Reinforces the compensation structure for key leadership roles.

Next Steps

• Continuous service by Kim D. Blickenstaff through the vesting dates.
• Potential exercise of stock options by Kim D. Blickenstaff upon vesting, subject to market conditions and personal financial planning.

Key Dates

Keywords

Nuvation Bio Inc., NUVB, Form 4, Stock Options, Director Compensation, Equity Grant, Beneficial Ownership, SEC Filing